Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
AEM Education and Training|July 28, 2018
Identifying the Emergency Medicine Personality: A Multisite Exploratory Pilot StudyJaime Jordan, Judith A Linden, Martine C Maculatis, et al.
Plos One|February 6, 2014
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic diseaseYoung Kwang Chae, Danai Khemasuwan, Anastasios Dimou, et al.
Rheumatology (Oxford, England)|December 14, 2020
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPYVibeke Strand, Namita Tundia, Alvin Wells, et al.
Rheumatology and Therapy|May 18, 2023
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension StudyAlan Kivitz, Alvin F Wells, Juan I Vargas, et al.
Modern Rheumatology|November 9, 2020
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY studyTsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
The Lancet. Rheumatology|January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialRoy Fleischmann, Alan Friedman, Edit Drescher, et al.
Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.
The American Journal of Psychiatry|August 3, 2004
Physical health monitoring of patients with schizophreniaStephen R Marder, Susan M Essock, Alexander L Miller, et al.
Pageof 9